UEGW 2022

IBD in 2022

Fast recapture of response with ozanimod after withdrawal in UC

Presented By

Dr Anita Afzali, University of Cincinnati College of Medicine, OH, USA

Trial

Phase 3, True North

Conference

UEGW 2022

1 December, 2022 22:08

Ozanimod treatment prompted substantial response after failure of response to induction

Presented By

Prof. Remo Panaccione, University of Calgary, Canada

Trial

Phase 3, True North

Conference

UEGW 2022

1 December, 2022 22:06

Etrasimod shows advantage over placebo in UC

Presented By

Prof. Séverine Vermeire, University Hospital Leuven, Belgium

Trial

Phase 3, ELEVATE UC

Conference

UEGW 2022

1 December, 2022 22:03

Etrasimod reduces adaptive immune cells in the periphery in UC

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 3, ELEVATE UC

Conference

UEGW 2022

1 December, 2022 22:00

Favourable maintenance rates for risankizumab also in delayed responders with CD

Presented By

rof. Geert D’Haens, Amsterdam UMC, the Netherlands

Trial

Phase 3, FORTIFY

Conference

UEGW 2022

1 December, 2022 21:56

IL-23 inhibition reduces inflammatory biomarkers in pre-treated UC

Presented By

Prof. Julian Panés, Hospital Clínic Barcelona, Spain

Trial

Phase 2, QUASAR

Conference

UEGW 2022

1 December, 2022 21:53

Maintained symptom control with mirikizumab in UC

Presented By

Prof. Axel Dignass, Agaplesion Markus Hospital, Germany

Trial

Phase 3, LUCENT 2

Conference

UEGW 2022

1 December, 2022 21:49

Mirikizumab successfully resolves active histologic inflammation in UC

Presented By

Prof. Fernando Magro, CHU de São João, Portugal

Trial

Phase 2, LUCENT 2

Conference

UEGW 2022

1 December, 2022 21:44

Upadacitinib for CD: remarkable efficacy in induction therapy

Presented By

Prof. Julian Panés, Hospital Clínic Barcelona, Spain

Trial

Phase 3, U-EXCEL

Conference

UEGW 2022

1 December, 2022 21:42

Sustained maintenance results with upadacitinib in UC

Presented By

Prof. Séverine Vermeire, University Hospital Leuven, Belgium

Trial

U-ACHIEVE Maintenance

Conference

UEGW 2022

1 December, 2022 21:37

Start low with brepocitinib and ritlecitinib in UC

Presented By

Dr Kenneth Hung, Pfizer, MA, USA

Trial

Phase 2, VIBRATO

Conference

UEGW 2022

1 December, 2022 21:34

Another chance for TYK2 inhibition in UC

Presented By

Prof. Stephan Schreiber, University Hospital Schleswig-Holstein, Germany

Trial

Phase 2, LATTICE-UC

Conference

UEGW 2022

1 December, 2022 21:29

Small molecule obefazimod shows promise in UC

Presented By

Prof. Séverine Vermeire, University Hospital Leuven, Belgium

Conference

UEGW 2022

1 December, 2022 21:26

Pivotal results of etrolizumab for CD partly disappointing

Presented By

Prof. Séverine Vermeire, University Hospital Leuven, Belgium

Trial

Phase 3, BERGAMOT

Conference

UEGW 2022

1 December, 2022 17:27

Better results for vedolizumab in early CD

Presented By

Prof. Geert D’Haens, Amsterdam UMC, the Netherlands

Trial

Phase 4, LOVE-CD

Conference

UEGW 2022

1 December, 2022 17:19

Some patients with limited CD may benefit from an early surgical intervention

Presented By

Dr Melek Zahra Sarikaya, Sjællands Universitetshospital, Denmark

Trial

LIR!C

Conference

UEGW 2022

1 December, 2022 17:11

Dose-interval of adalimumab might be prolonged in CD patients in stable remission

Presented By

Dr Reinier van Linschoten , Franciscus Gasthuis en Vlietland, the Netherlands

Trial

Phase 4, LADI

Conference

UEGW 2022

1 December, 2022 17:01

What Is Hot in Upper GI Disorders?

Less ulcer bleeds early after H. pylori eradication in aspirin users

Presented By

Prof. Christopher Hawkey, Nottingham Digestive Diseases Centre, UK

Trial

Phase 4, HEAT

Conference

UEGW 2022

2 December, 2022 09:08

Dupilumab effective in paediatric patients with eosinophilic oesophagitis

Presented By

Prof. Evan S. Dellon, University of North Carolina School of Medicine in Chapel Hill, NC, USA

Trial

Phase 3, EoE KIDS

Conference

UEGW 2022

2 December, 2022 09:04

Neoplasia in Barrett’s oesophagus: the earlier the intervention, the better the long-term outcome

Presented By

Dr Fadi Younis, University Hospital Hamburg-Eppendorf, Germany

Conference

UEGW 2022

2 December, 2022 09:00

Hepatology in 2022

Favourable pancreatitis outcomes with procalcitonin-based algorithm to guide antibiotic use

Presented By

Prof. Ajith Siriwardena, Manchester Royal Infirmary, UK

Trial

PROCAP

Conference

UEGW 2022

2 December, 2022 09:35

Portal hypertension is associated with poor prognosis in cirrhotic patients

Presented By

Mr Phil Ambery, AstraZeneca, Sweden

Conference

UEGW 2022

2 December, 2022 09:18

Chances of transplant-free survival in PSC enhanced by colectomy with ileostomy

Presented By

Dr Bregje Mol, Amsterdam UMC, the Netherlands

Conference

UEGW 2022

2 December, 2022 09:13

SARS-CoV-2: Booster doses of key importance for cirrhotic patients

Presented By

Dr Samer Al-Dury, Sahlgrenska University Hospital, Sweden

Conference

UEGW 2022

2 December, 2022 09:11

What Is New in Pancreatic Cancer and Pancreatitis?

Colorectal Carcinoma: Improving Diagnosis and Therapy

Immunotherapy response may be modulated by microbiome

Presented By

Dr Johannes Björk, University Medical Center Groningen, the Netherlands

Trial

PRIMM

Conference

UEGW 2022

2 December, 2022 09:48

Computer-aided colonoscopies improved adenoma detection rates

Presented By

Dr Michiel Maas, Raboud UMC, the Netherlands

Conference

UEGW 2022

2 December, 2022 09:44

Screening-detected colorectal cancers may have superior surgical outcomes

Presented By

Dr Jannie Dressler, Bispebjerg Hospital, Denmark

Conference

UEGW 2022

2 December, 2022 09:37